FRANKLIN LAKES, N.J.,
April 23, 2017 /PRNewswire/
-- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading
global medical technology company, announced today the appointment
of Tom Polen, 43, as president of
BD, effective immediately. In his new role, Mr. Polen will oversee
all of BD's operating segments – the Medical and Life Sciences
segments, as well as the new Interventional segment, which will
include the C. R. Bard, Inc. (NYSE: BCR) businesses following the
close of BD's acquisition of Bard, which was also announced today.
Mr. Polen, currently executive vice president and president of the
BD Medical Segment, will continue to report to Vince Forlenza, who remains chairman and CEO of
BD.
"Tom brings a deep understanding of BD, the medical technology
industry and the global healthcare environment," said Vince Forlenza, chairman and CEO of BD. "His
well-deserved promotion reflects his leadership in developing and
implementing BD Medical's strategy and vision, his proven track
record of delivering strong performance, and his commitment to
ensuring the ongoing success of BD and its associates. I look
forward to continuing to work closely with the Board, Tom, our
entire leadership team, and our associates to successfully
integrate and grow the combined company in the years ahead, as we
deliver on our purpose of advancing the world of health."
Mr. Polen said, "This is an exciting time for BD. I am
honored to serve in this new role as we continue our transformation
into a medical technology leader focused on delivering solutions
that advance the discovery, diagnostics and delivery of health care
globally and helping health care providers worldwide to improve
both the process of care and the treatment of disease."
Mr. Polen originally joined BD in 1999. His BD career has
spanned sales, marketing, general management and strategic planning
roles. In 2004, Mr. Polen joined Baxter Healthcare, where he last
served as General Manager of Baxter's Global Pharmaceutical
Injectables business. Since rejoining BD in 2009, Mr. Polen has
worked in or had responsibility for a range of businesses in the
company, including roles as worldwide president, BD Preanalytical
Systems; worldwide president, BD Diagnostics Systems; group
president, BD Medical Surgical Systems and BD Pharmaceutical
Systems. In October 2014, Mr. Polen
was named executive vice president and president of the BD Medical
segment.
Mr. Polen holds an MBA from Johns Hopkins
University and a bachelor's degree from the University of
Maryland.
About BD
BD is a global medical technology company
that is advancing the world of health by improving medical
discovery, diagnostics and the delivery of care. BD leads in
patient and health care worker safety and the technologies that
enable medical research and clinical laboratories. The company
provides innovative solutions that help advance medical research
and genomics, enhance the diagnosis of infectious disease and
cancer, improve medication management, promote infection
prevention, equip surgical and interventional procedures, and
support the management of diabetes. The company partners with
organizations around the world to address some of the most
challenging global health issues. BD has nearly 50,000 associates
across 50 countries who work in close collaboration with customers
and partners to help enhance outcomes, lower health care delivery
costs, increase efficiencies, improve health care safety and expand
access to health. For more information on BD, please visit
bd.com.
BD
Monique N. Dolecki, Investor
Relations – (201) 847-5378
Kristen Cardillo, Corporate
Communications – (201) 847-5657
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bd-announces-appointment-of-tom-polen-as-president-300443956.html
SOURCE BD (Becton, Dickinson and Company)